MedTrace Logo

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

NCT03219970 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2021-09-14

No results posted yet for this study

Summary

To assess the efficacy of single-agent osimertinib in relation to EGFR T790M mutant allele fraction (AF) in a real-world setting.

Conditions

Interventions

DRUG

Osimertinib

80mg oral daily

Sponsors & Collaborators

Principal Investigators

  • Siu Hong, Oscar CHAN · Pamela Youde Nethersole Eastern Hospital

  • Kwok Chi LAM · Prince of Wales Hospital

  • Ho Fun, Victor LEE · Queen Mary Hospital, Hong Kong

  • Shi Feng NYAW · Tuen Mun Hospital

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-05
Primary Completion
2020-10-28
Completion
2020-10-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219970 on ClinicalTrials.gov